Patricia Jaaks

Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.

Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.

Journal: Nature cancer

Published: June 17, 2024

A pan-cancer screen identifies drug combination benefit in cancer cell lines at the individual and population level.

A pan-cancer screen identifies drug combination benefit in cancer cell lines at the individual and population level.

Journal: Cell reports. Medicine

Published: January 22, 2024

Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.

Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.

Journal: Nature cancer

Published: May 22, 2023

Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations.

Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations.

Journal: Cancer discovery

Published: April 04, 2023

AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.

AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.

Journal: Oncogene

Published: May 03, 2022

Effective drug combinations in breast, colon and pancreatic cancer cells.

Effective drug combinations in breast, colon and pancreatic cancer cells.

Journal: Nature

Published: July 02, 2021

Patient-specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies.

Patient-specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies.

Journal: Molecular systems biology

Published: January 13, 2021

Integrated cross-study datasets of genetic dependencies in cancer.

Integrated cross-study datasets of genetic dependencies in cancer.

Journal: Nature communications

Published: December 18, 2020

SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.

SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.

Journal: British journal of cancer

Published: June 02, 2020

AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia.

AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 19, 2020

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib.

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib.

Journal: Molecular cancer therapeutics

Published: January 07, 2020

Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens.

Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens.

Journal: Molecular systems biology

Published: December 18, 2019

Showing 1-12 of 21

Last Updated: 09/26/2026